Charles Schwab Investment Management Inc. grew its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 14.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 600,819 shares of the company's stock after purchasing an additional 73,623 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.08% of Enovis worth $25,865,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the company. River Road Asset Management LLC acquired a new stake in shares of Enovis during the third quarter worth $51,341,000. American Century Companies Inc. raised its position in shares of Enovis by 78.6% during the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company's stock worth $68,337,000 after purchasing an additional 665,208 shares during the period. Magnetar Financial LLC boosted its position in Enovis by 66.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company's stock valued at $49,937,000 after purchasing an additional 442,051 shares during the period. Diamond Hill Capital Management Inc. increased its position in Enovis by 14.5% in the second quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company's stock worth $125,929,000 after buying an additional 352,116 shares during the period. Finally, Royce & Associates LP lifted its stake in Enovis by 16.8% in the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company's stock valued at $103,479,000 after buying an additional 346,317 shares during the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
ENOV has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a report on Thursday, August 8th. Evercore ISI reduced their price objective on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research report on Tuesday, October 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. Finally, JMP Securities initiated coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, Enovis has an average rating of "Moderate Buy" and an average price target of $67.00.
Check Out Our Latest Report on Enovis
Enovis Stock Down 1.5 %
NYSE:ENOV traded down $0.74 on Thursday, hitting $47.88. 507,852 shares of the company's stock traded hands, compared to its average volume of 582,121. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.68 billion, a PE ratio of -21.79 and a beta of 1.94. The firm has a 50-day moving average price of $43.53 and a 200-day moving average price of $44.78. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03.
Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same period last year, the company earned $0.56 earnings per share. Enovis's quarterly revenue was up 21.0% compared to the same quarter last year. Equities analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.
Enovis Profile
(
Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Featured Stories
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.